{"id":30436,"date":"2020-11-11T18:40:29","date_gmt":"2020-11-11T18:40:29","guid":{"rendered":"https:\/\/amelie-project.eu\/?post_type=press-release&p=30436"},"modified":"2021-05-08T07:38:26","modified_gmt":"2021-05-08T07:38:26","slug":"eu-unterstutzt-bahnbrechende-forschung-auf-dem-gebiet-der-inkontinenz-mit-9-mio-e","status":"publish","type":"press-release","link":"https:\/\/amelie-project.eu\/de\/presseerklarung\/eu-unterstutzt-bahnbrechende-forschung-auf-dem-gebiet-der-inkontinenz-mit-9-mio-e\/","title":{"rendered":"EU unterst\u00fctzt bahnbrechende Forschung zur Inkontinenz mit 9,5 Mio. Euro"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.6.3″ custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.6.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” module_alignment=”center” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.3″ text_font=”Gotham kinda bold||||||||” text_text_color=”#000000″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”]<\/p>\n

Die EU hat 9,5 Mio. Euro f\u00fcr ein bahnbrechendes Forschungsprojekt zur Behandlung von Stuhlinkontinenz bereitgestellt.<\/p>\n

Ziel der Forschung ist es, mit Hilfe einer revolution\u00e4ren Zelltherapie eine m\u00f6gliche Heilung f\u00fcr eine Krankheit zu finden, von der sch\u00e4tzungsweise 67 Millionen Menschen in Europa betroffen sind.<\/p>\n

Die Mittel gehen an ein Konsortium von 13 Organisationen aus neun L\u00e4ndern mit dem Namen AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n

Das Projekt wird vom UCL koordiniert und von Richard Day, Professor f\u00fcr Regenerative Medizintechnologie am UCL, geleitet.<\/p>\n

Zu den weiteren Partnern im Vereinigten K\u00f6nigreich geh\u00f6ren die Queen Mary University of London, NHS Blood and Transplant und die Wohlt\u00e4tigkeitsorganisation Bowel Research UK, die die Federf\u00fchrung bei der Einbeziehung der Patienten \u00fcbernehmen wird.<\/p>\n

Die Forschungsarbeiten werden \u00fcber einen Zeitraum von f\u00fcnf Jahren durchgef\u00fchrt, wobei in jeder neuen Phase verschiedene Einrichtungen im Vereinigten K\u00f6nigreich, Spanien und Portugal die Federf\u00fchrung \u00fcbernehmen.<\/p>\n

Im Mittelpunkt des Projekts steht die Entnahme patienteneigener Muskelzellen, die auf speziell entwickelte Mikrotr\u00e4ger geladen und in den gesch\u00e4digten Muskel implantiert werden, um die Regeneration zu f\u00f6rdern und die normale Funktion wiederherzustellen.<\/p>\n

Professor Day sagte, dass eine solche Therapie der regenerativen Medizin vielen Menschen, deren Leben durch Inkontinenz stark beeintr\u00e4chtigt ist, Hoffnung gibt:<\/p>\n

\u201cWir sind von der Aussicht auf das AMELIE-Projekt und den potenziellen Vorteilen, die sich aus dem untersuchten neuen therapeutischen Ansatz ergeben k\u00f6nnten, sehr begeistert.<\/p>\n

\u201cWir freuen uns auf die Zusammenarbeit mit dem au\u00dfergew\u00f6hnlichen Konsortium aus Wissenschaftlern, Klinikern, Industrie und Wohlfahrtsverb\u00e4nden aus ganz Europa, um unseren bahnbrechenden Ansatz der regenerativen Medizin zur Behandlung dieser schw\u00e4chenden Krankheit weiterzuentwickeln.<\/p>\n

\u201cDies ist ein radikaler und innovativer Ansatz, der in dieser Gr\u00f6\u00dfenordnung noch nie versucht wurde.\u201d<\/p>\n

Lesley Booth MBE, Direktorin f\u00fcr Forschung und PPI bei Bowel Research UK, sagte, dass die Krankheit zwar sehr h\u00e4ufig vorkomme, aber nicht viel dar\u00fcber gesprochen werde.<\/p>\n

\u201cDie Realit\u00e4t eines Lebens mit Stuhlinkontinenz kann verheerend sein. Sie ist definitiv lebensbegrenzend. Und die Tatsache, dass es sich um eine Krankheit handelt, \u00fcber die nicht offen gesprochen wird, erschwert die F\u00fchrung eines normalen Lebens noch zus\u00e4tzlich\u201d, sagte sie.<\/p>\n

\u201cEine Therapie zu finden, die funktioniert, w\u00e4re nicht nur ein gro\u00dfer medizinischer Durchbruch, sondern w\u00fcrde das Leben von Millionen von Menschen ver\u00e4ndern.\u201d<\/p>\n

Dieses Projekt wurde von der Europ\u00e4ischen Union im Rahmen des Forschungs- und Innovationsprogramms Horizont 2020 mit der Finanzhilfevereinbarung Nr. 874807 gef\u00f6rdert.<\/p>\n

\n

<\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/amelie-project.eu\/wp-content\/uploads\/2021\/01\/Picture-1.png” title_text=”Picture 1″ _builder_version=”4.6.3″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence. The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE). The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL. Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement. The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage. The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function. Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence: \u201cWe are tremendously excited by the prospect of the AMELIE project […]<\/p>","protected":false},"featured_media":31025,"template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\n

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence.<\/p>\n\n\n\n

The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. <\/p>\n\n\n\n

The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n\n\n\n

The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL.<\/p>\n\n\n\n

Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement.<\/em><\/p>\n\n\n\n

The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage.<\/p>\n\n\n\n

The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function.<\/p>\n\n\n\n

Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence:<\/p>\n\n\n\n

\u201cWe are tremendously excited by the prospect of the AMELIE project and the potential benefits that may arise from the new therapeutic approach being investigated.<\/p>\n\n\n\n

\u201cWe look forward to working with the exceptional consortium of academics, clinicians, industry and charity partners from across Europe to develop our pioneering regenerative medicine approach for treating this debilitating condition.<\/p>\n\n\n\n

\u201cThis will be a radical and innovative approach never before attempted at such a scale.\u201d<\/p>\n\n\n\n

Lesley Booth MBE, Director of Research and PPI at Bowel Research UK, said that, whilst the condition is extremely common, it is not much talked about.<\/p>\n\n\n\n

\u201cThe reality of living with faecal incontinence can be devastating. It is definitely life-limiting. And the fact that it\u2019s a condition which people don\u2019t discuss freely just adds to the difficulties of leading a normal life,\u201d she said.<\/p>\n\n\n\n

\u201cFinding a therapy which works would not just be a major medical breakthrough, it would be life-changing for millions.\u201d<\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

Ends<\/strong><\/p>\n\n\n\n

NOTES TO EDITORS<\/strong><\/p>\n\n\n\n

AMELIE<\/strong> (Anchored Muscle cELls for IncontinencE consortium) is made up of the following: University College London, Instituto Superior Tecnico (Portugal), Queen Mary University of London, Medical University of Graz (Austria), Aarhus University Hospital (Denmark), Rouen University Hospital (France), University Hospital Erlangen (Germany), Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (Spain), NHS Blood and Transplant (UK), Polysciences Europe GmbH (Germany), Ttopstart (Netherlands), Bowel Research (UK), Consorzio per Valutazioni Biologiche e Farmacologiche (Italy).<\/p>\n\n\n\n

Horizon 2020<\/strong> is an EU funding programme for research and innovation. It is the biggest EU Research and Innovation programme ever with nearly \u20ac80 billion of funding available over 7 years (2014 to 2020) \u2013 in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. https:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/what-horizon-2020<\/a><\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

AMELIE contact:<\/strong><\/p>\n\n\n\n

Media contact:<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_links_to":"","_links_to_target":""},"categories":[51],"class_list":["post-30436","press-release","type-press-release","status-publish","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/amelie-project.eu\/de\/wp-json\/wp\/v2\/press-release\/30436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amelie-project.eu\/de\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/amelie-project.eu\/de\/wp-json\/wp\/v2\/types\/press-release"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amelie-project.eu\/de\/wp-json\/wp\/v2\/media\/31025"}],"wp:attachment":[{"href":"https:\/\/amelie-project.eu\/de\/wp-json\/wp\/v2\/media?parent=30436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amelie-project.eu\/de\/wp-json\/wp\/v2\/categories?post=30436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}